Analysis of Percutaneous Ablations for Cancer Treatment
This is a study involving patients with cancer who are referred by their treating physician for percutaneous locoregional therapies.
Patient's clinical and radiology findings, pathology findings, survival, treatment responses, and complications after their locoregional therapy will be studied.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Prospective Analysis of Percutaneous Ablations for Cancer Treatment|
- Effect of percutaneous and transarterial treatments for cancer in quality of life [ Time Frame: 1 year ]Patients will complete the QOL questionnare during their follow up visits after procedure. 1 month, 3 months, 6 months and 1 year.
- response rate to percutaneous and transarterial treatment for cancer [ Time Frame: 1 month, 3 months, 6 months, 1 year. ]Patients will be followed up 1, 3, 6 and 1year intervals after procedure.
|Study Start Date:||February 2012|
|Study Completion Date:||January 2014|
|Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
The efficacy of the percutaneous and transarterial treatments for solid tumors will be studied. Prospective study on patients who receive percutaneous locoregional therapies, including radiofrequency ablation (RFA), cryoablation, microwave ablation, IRE and chemical ablation for treatment of cancer will be performed.
Preoperative clinic chart, procedure note, postoperative chart, pre- and post-operative CT, MRI or Ultrasound, angiographic findings, biopsy results and pathologic findings, will be reviewed. Patient survival, treatment responses, complications after the therapy will be collected from clinic visits and clinical encounters.
Patient overall performance status before and after procedures will be assessed using the Quality of Life questionnaire (SF-36™ Health Survey).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01563679
|United States, Georgia|
|Emory University Hospital|
|Altanta, Georgia, United States, 30322|
|Principal Investigator:||Hyun S Kim, MD||Emory University|